ASCO 2021: 摘要概览与展望 2

2021-05-23 JACKZHAO MedSci原创

对于肿瘤学股追随者来说,Asco摘要的发布是一年中最大的事件,尽管连续第二年进行虚拟化,但2021年看起来仍将提供重要更新的一部分。梅斯医学将带领大家了解最近进展~ENJOY!

ASCO 2021:摘要概览与展望 1

<a href='https://www.medsci.cn/search?q=ASCO'>ASCO</a> Annual Meetings | Cancer.Net

 

对于肿瘤学学术进展随者来说,Asco摘要的发布是一年中最大的事件之一,尽管连续第二年进行虚拟化,但2021年看起来仍将提供重要更新的一部分。梅斯医学将带领大家了解最近进展~ENJOY!

然而,许多最重要的数据仍处于保密状态,最新的摘要将于6月3日美国东部时间下午5点(会议召开的前一天)发布。

重要的Asco最新摘要节选

 

重点关注的Asco最新摘要结果预告节选1:

  • 阿斯利康/默沙东Lynparza(利普卓)(Merck&Co Lynparza Olympia):PH(3)辅助化疗后,Lynparza在种系BRCA1 / 2突变和高风险HER2阴性早期乳腺癌中进行(新)辅助化疗后的试验
  • 默沙东Keynote-564:Keytruda作为肾切除术后辅助治疗肾细胞癌的ph3试验
  • 诺华177Lu-PSMA-617:177Lu-PSMA-617在转移性去势抵抗性前列腺癌中的第3期临床试验
  • 君实生物和Coherus Biosciences 拓益Jupiter-02:拓益(toripalimab)联合化学治疗复发或转移性鼻咽癌的一线治疗的ph3试验
  • BMS Opdivo和Yervoy Checkmate-648:Opdivo加Yervoy等化学疗法作为晚期食道鳞状细胞癌的一线治疗CheckMate 648研究的第一项结果。重要精选摘要目录:
重要精选摘要目录
公司 项目 药物作用机制 摘要序列号 题目概述
Adaptimmune Afami-cel Anti-Mage-A4 eTCR 11504 Adaptimmune’s T-cell receptors see a route to market
Alkermes Nemvaleukin IL-2 mimic 2513 Responses seen in monotherapy and with Keytruda across various tumours 
Allogene ALLO-501 Anti-CD19 allo Car-T 2529 Off-the-shelf cell therapy inches towards reality
Alpine Immune ALPN-202 Conditional CD28 costimulator and dual checkpoint inhibitor 2547 Ph1 dose escalation; 1 unconfirmed PR and 5 SD in 11 subjects
Arcus Etrumadenant + zimberelimab + AB680 A2aR/A2bR antagonist + anti-PD-1 + anti-CD73 5039 In evaluable pts, PSA response 5/14, radiographic response 3/8, with 1 CR, composite response rate was 43% (6/14)
Black Diamond BDTX-189  EGFR/HER2 kinase inhibitor 3086 Of 15 evaluable, 1 confirmed PR, 3 SD and 10 progressive disease
Bristol Myers Squibb Relatlimab Anti-Lag3 MAb 9503 Bristol’s Lag3 case for a replacement for Yervoy
Cullinan CLN-081 EGFR Exon20 inhibitor 9077 Of 25 evaluable, 10 PRs, 14 SD, 1 progressive disease. Later cut to be presented
G1 Rintodestrant  SERD 1063 Ph1 safety data: rintodestrant-related AEs in 8%, all grade 2
I-Mab Uliledlimab Anti-CD73 MAb 2511 Of 13 evaluable, 3 CRs or PRs (ORR 23%) and 3 SD (disease control rate 46%).
Immunogen Mirvetuximab Anti-FRα ADC 5504 Of 33 pts with high FRα expression ORR 64%, mDOR of 11.8 months, and mPFS of 10.6 months (Forward I study failed in all-comers)
Immutep eftilagimod alpha Lag3  9046; 6028; 2518  Data from ongoing Ph2 trials in combination with Keytruda (NSCLC & H&N), and Ph1 plus Bavencio.  
Kadmon KD033  Anti-PD-L1/IL-15 fusion protein  2568 Of 6 evaluable, 1 SD
Macrogenics MGC018  Anti-B7-H3 ADC 2631 3 unconfirmed PRs in melanoma pts
Merus Zenocutuzumab Anti-Her2/Her3 bispecific 3003 Merus intrigues in pancreatic cancer
Roche Tecentriq Anti-PD-L1 MAb 8500 Adjuvant lung cancer beckons for Tecentriq, but only in PD-L1 expressers
SQZ Biotechnologies SQZ-PBMC-HPV-101 

T-cell surface glycoprotein CD8 stimulant

2536 4 SD in 10 evaluable pts 
Sutro STRO-002  FRα inhibitor 5550 Of 31 evaluable, 1 CR, 4 confirmed PR, and 5 unconfirmed PR. Disease control rate was 74% at 12 weeks and 61% at 16 weeks. 
Sensei  SNS-301 ASPH targeted bacteriophage  6029 67% response rate in 12 PD-1 refractory H&N patients 
PDS Biotech PDS0101 HPV targeted T cell activator  2501 In combination with M9241 and bintrafusp alpha, ORR of 71%

当然,这还远远没有详尽地介绍重要的口头演讲,并且在接下来的几周内将有更多的数据发布,尽请保持关注!

更多内容关注梅斯医学ASCO专题页:https://meeting.medsci.cn/ASCO2020

参考来源:https://meetinglibrary.asco.org/results?meetingView=2021%20ASCO%20Annual%20Meeting

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1939164, encodeId=95001939164bb, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jun 11 12:00:57 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968001, encodeId=b7f496800180, content=点赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28755506535, createdName=徐沐沐, createdTime=Sun May 23 20:30:03 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967986, encodeId=df5796e98673, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104283, encryptionId=dbe71042839b, topicName=ASCO2021)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Sun May 23 19:27:39 CST 2021, time=2021-05-23, status=1, ipAttribution=)]
    2021-06-11 quxin068
  2. [GetPortalCommentsPageByObjectIdResponse(id=1939164, encodeId=95001939164bb, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jun 11 12:00:57 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968001, encodeId=b7f496800180, content=点赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28755506535, createdName=徐沐沐, createdTime=Sun May 23 20:30:03 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967986, encodeId=df5796e98673, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104283, encryptionId=dbe71042839b, topicName=ASCO2021)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Sun May 23 19:27:39 CST 2021, time=2021-05-23, status=1, ipAttribution=)]
    2021-05-23 徐沐沐

    点赞

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1939164, encodeId=95001939164bb, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Jun 11 12:00:57 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968001, encodeId=b7f496800180, content=点赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28755506535, createdName=徐沐沐, createdTime=Sun May 23 20:30:03 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967986, encodeId=df5796e98673, content=<a href='/topic/show?id=dbe71042839b' target=_blank style='color:#2F92EE;'>#ASCO2021#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104283, encryptionId=dbe71042839b, topicName=ASCO2021)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Sun May 23 19:27:39 CST 2021, time=2021-05-23, status=1, ipAttribution=)]

相关资讯

随着COVID-19大流行的继续,ASCO年会即将在线举行

美国临床肿瘤学会(American Society of Clinical Oncology,ASCO)成立于1964年, 是全球领先的肿瘤专业学术组织,旨是预防癌症及改善癌症服务。

ASCO 2020:肺鳞癌免疫治疗新突破,百济神州展现中国“研”值

2020年5月29日,全球肿瘤界的年度盛会——美国临床肿瘤学会(ASCO)年会正式揭开序幕。

ASCO 2021:摘要概览与展望 1

美国临床肿瘤学会(ASCO)年度会议将在2021年6月4日至8日举行。公司和研究人员已经开始宣布他们的计划,以提供数百份(有时来自一家公司)新的摘要和报告的计划。 各种适应症和治疗设置的临床研究范围。

ASCO 2021:天境生物公布其CD73抗体的1期临床研究成果,初步显示疗效信号

美国临床肿瘤学会(ASCO)年会作为迄今为止规模最大、最具权威性、学术水平最高的临床肿瘤学会议之一,备受生物医药领域瞩目。

ASCO 前沿:CAR-T疗法治疗复发/难治性淋巴瘤重大突破汇总

ASCO 前沿,CAR-T疗法治疗复发/难治性淋巴瘤重大突破汇总。

ASCO 前沿:肝癌的重磅研究盘点

ASCO 前沿,肝癌的重磅研究盘点